Chronic exposure to low levels of mold has been reported to increase susceptibility to respiratory infections. Currently, the mechanism is not well understood. This study investigated lung defense effects after repeated low-dose zymosan (a 1-->3-beta-glucan from yeast cell wall) exposure on bacterial infection (Listeria monocytogenes) in male Sprague-Dawley rats. On days 0, 3, 7 and 10, rats received one dose of zymosan A (0.6 mg/kg body weight each dose) via intratracheal instillation or vehicle control (saline). On day 17 (one week later), rats were intratracheally inoculated with 5x105 bacteria. Rats were euthanized on days 20, 22, and 24. Bacterial clearance was determined by measuring colony-forming units cultured from the left lungs. Bronchoalveolar lavage (BAL) was performed on the right lungs. Inflammation and lung injury were assessed by measuring (1) neutrophil (PMN) infiltration and (2) albumin and lactate dehydrogenase levels in BAL fluid. Multiple zymosan treatments induced greater lung injury and inflammation as indicated by elevations in PMN, LDH, and albumin at days 22 and 24 compared to control. In addition, repeated low-dose exposure to zymosan slowed the clearance of the bacteria at day 20 and 22 compared to controls, suggesting a possible suppression in lung immune responses. In contrast, previous results have shown that a single acute dose of zymosan at a concentration (2.5 mg/kg body-weight) equivalent to the total of the four repeated concentrations used in the current study enhanced lung immune responses and increased the rate of bacterial clearance from the lung. This study demonstrated the importance of treatment concentration and dosing regimen in understanding lung immune effects associated with 1-->3-beta-glucan exposure.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.